Track 1: Translational Radiooncology

Track 2: Molecular Radiooncology

Track 3: Nuclear Medicine

Track 4: Immunooncology Research

Track 5: Dosimetry & Treatment Planning

Track 6: Computer assisted tomography

Track 7: Advanced Radiation Therapies and technologies

Track 8: Clinical trials in Cancer Treatment

Track 9: Nanotechnology in Radiooncology

Track 10: Biomarkers in Radiooncology

Track 11; Applied Radiation Biology

Track 12: Medical informatics

Track 13: Medical Radiation Physics

Track 14: Combinatorial therapies

Track 15: Outcomes of new radiotherapy techniques

Track 16: Pediatric Radiooncology

Radiooncology Organizations in USA:

• American Association of Medical Dosimetrists (AAMD)
• American Brachytherapy Society (ABS)
• American College of Radiation Oncology (ACRO)
• American Society for Therapeutic Radiology and Oncology (ASTRO)
• American College of Radiology (ACR)
• American Healthcare Radiology Administrators (AHRA)
• American Institute of Ultrasound in Medicine (AIUM)
• American Roentgen Ray Society (ARRS)
• British Institute of Radiology (BIR)

 

 

Cancer is a disease characterized by uncontrolled cell proliferation. Of the more than 100 types of cancer, lung, breast, and colorectal cancer account for nearly half of new cases per year in the United States. Lung cancer, which is highly correlated with cigarette smoking, is responsible for more deaths than any other form of cancer. Cigarette smoking and other environmental factors are associated with the majority of cancers. Increasing Patient Assistance Programs (PAP’s), growing government initiatives for cancer awareness, rising prevalence of cancer worldwide, and strong R&D initiatives from key players are the major factors fueling the growth of the cancer therapy market. The cancer therapy market was valued at USD 125730.7 million in 2017, is expected to register a CAGR of about 8.37% during the forecast period, 2018-2023. Cancer is one of the leading causes of morbidity and mortality, globally. According to World Health Organization (WHO), in 2015, cancer was the second leading cause of death accounting for 8.8 million deaths, worldwide, and the number of new cancer cases is expected to rise by about 70% over the next two decades. It has been identified that approximately 70% of deaths from cancer occur in low- and middle-income countries. Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per the World Cancer Report. The growing incidence and prevalence of cancer and launch of novel cancer therapy, coupled with increasing awareness about cancer cure and treatment, are likely to drive the growth of the global cancer therapy market during the forecast period.

Additionally, increasing Patient Assistance Programs (PAP’s), growing government initiatives for cancer awareness, and strong R&D Initiatives from key players are anticipated to drive the market for global cancer therapies.

What makes the growth of Cancer Therapy market?

The annual growth rate in cancer drug costs skyrocketed from 3.8% in 2011 to 11.5% in 2015, at a constant exchange rate. Growth in the American market rose from 2.0% to 13.9% during the same time period. The United States now accounts for almost 45% of the global market for oncology therapeutics, up from 39% in 2011, owing to the strengthening of the US dollar and the rapid adoption of innovative, novel and newer therapies. In the United States, oncology drugs account for more than 11.5% of the total drug costs, up from 10.5% in 2011. Net price growth in the United States, on established branded oncology drugs, had averaged an estimated 4.8% in 2015, as compared to 6.4% invoice price growth. Factors, such as longer duration of cancer therapies, availability of novel agents, and use of combination therapy are contributing to the rising cost of cancer therapy. Thus, the rising cost of cancer therapies, coupled with the fluctuation of reimbursement policies for cancer treatment across the globe, is likely to impede the growth of the global cancer therapy market.

North America’s role in the Cancer Therapy Market

North America dominates the global cancer therapy market, owing to a high prevalence of cancer in the region because of a sedentary lifestyle, along with launch and growing adoption of novel cancer therapy in the region. USFDA is taking steps to enhance the growth of the cancer therapy market by approving drugs that are in clinical phase, thus, accelerating the clinical developments. Companies and research organizations are investing in R&D activities. Hence, the market is expanding at a faster pace.

Key Developments in the Cancer Therapy Market:

February 2018: Bristol-Myers Squibb Company announced cancer deal with Nektar Therapeutics. As per the deal, Bristol-Myers Squibb Company will pay USD 1.85 billion to Nektar Therapeutics. The partnership is built around the Nektar drug, NKTR-214, which will be tested in combination with Bristol’s immuno-oncology (IO) drugs Opdivo and Opdivo and Yervoy in 20 cancer indications across nine different tumor types, including melanoma, kidney, and lung cancers

January 2018: AstraZeneca and Merck & Co., Inc., received approval from US Food and Drug Administration, for Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.

The major players include Amgen, AstraZeneca, Bristol-Myers Squibb, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC., Johnson & Johnson., Merck & Co. Inc., Novartis AG, Pfizer Inc., among others.